The therapeutically effect amount of the at least one aminosterol or a salt or derivative thereof in the methods of the invention can be, for example, about 0.1 to about 20 mg/kg, about 0.1 to about 15 mg/kg, about 0.1 to about 10 mg/kg, about 0.1 to about 5 mg/kg, or about 0.1 to about 2.5 mg/kg body weight of the subject. In another aspect, administration of the at least one amino sterol or a salt or derivative thereof comprises non-oral administration. In another aspect, the at least one aminosterol or a salt or derivative thereof is administered nasally. Exemplary methods of administration include oral, nasal, sublingual, buccal, rectal, vaginal, intravenous, intra-arterial, intradermal, intraperitoneal, intrathecal, intramuscular, epidural, intracerebral, intracerebroventricular, transdermal, or any combination thereof. In one aspect, the at least one aminosterol or a salt or derivative thereof is administered via any pharmaceutically acceptable means. In one embodiment, the invention encompasses a method of treating, preventing and/or slowing the onset or progression of hallucinations and/or a related symptom in a subject in need comprising administering to the subject a therapeutically effective amount of at least one aminosterol or a salt or derivative thereof. Preferably the aminosterol is a pharmaceutically acceptable grade of the amino sterol. The amino sterol or a salt or derivative thereof can be formulated with one or more pharmaceutically acceptable carriers or excipients. Certain embodiments describe the determination and administration of a “fixed dose” of an aminosterol or a pharmaceutically acceptable salt or derivative thereof that is not age, size, or weight dependent but rather is individually calibrated. The present invention is directed to methods of treating, preventing, and/or slowing the onset or progression of hallucinations and/or a hallucination-related symptom in a subject in need comprising administering to the subject a composition comprising at least one aminosterol, or a salt or derivative thereof. The present invention satisfies this need. There is a need in the art for new methods of treating hallucinations. The most abundant source of squalamine is in the livers of Squalus acanthias, although it is found in other sources, such as lampreys (Yun et al., 2007).Īminosterol 1436 is an aminosterol isolated from the dogfish shark, which is structurally related to squalamine (U.S. Squalamine was discovered in various tissues of the dogfish shark ( Squalus acanthias) in a search for antibacterial agents. The discovery of squalamine, the structure of which is shown above, was reported by Michael Zasloff in 1993 (U.S. Squalamine is a unique compound with a structure that was not previously seen in nature, being a bile acid coupled to a polyamine (spermidine): The methods comprise administering to a subject in need thereof an amino sterol, or a salt or derivative thereof. This application relates to methods of treating, preventing, or improving disorders associated with hallucinations and/or hallucinations in human subjects. 7, 2019, the entire contents of which are incorporated herein by reference in their entirety. provisional Application 62/789,437, filed Jan. provisional Application 62/648,661, filed Mar. This application claims the priority benefits under 35 USC § 119 to U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |